TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9839762
Drug: Donepezil +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil + Cimetidine (5 mg + 800 mg)
Study: 2631519
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 1200 mg/day
Study: 2631519
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetylsalicylic acid (ASA, 1050 mg/day) and dipyridamole (D, 150 mg/day)
Study: 1023953
Drug: Aluminium hydroxide
Normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium hydroxide 40 ml
Study: 1023953
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate 30 ml
Study: 1023953
Drug: Magnesium trisilicate
Normalized name: Magnesium Trisilicate
DrugBank: Magnesium trisilicate (DB09281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium trisilicate 30 ml
Study: 1023953
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg alone
Study: 22999847
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (subacromial, intra-articular, intra-articular combined with subacromial)
Study: 22999847
Drug: Medication (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (control group IV)
Study: 17163358
Drug: Calcitriol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 1.5 mcg/die plus hydrochlorothiazide
Study: 9322806
Drug: tolrestat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolrestat (200 mg daily)
Study: 3919803
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g daily for one month
Study: 3919803
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg daily for one month
Study: 20925642
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg twice daily)
Study: 20925642
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg twice daily) + Topical honey ointment
Study: 20925642
Drug: Standard burn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard burn treatment (Control group)
Study: 11090092
Drug: Thalidomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200 mg orally per day, increased to 800 mg/d if tolerable)
Study: 8475869
Drug: Extended-release gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-release gemfibrozil 1,200 mg once daily
Study: 3894608
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated bovine rotavirus vaccine strain RIT 4237
Study: 26067078
Drug: Canned chickpea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canned chickpea (200 g per day)
Study: 26067078
Drug: Raffinose (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raffinose (5 g)
Study: 15883316
Drug: CSF examination
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSF examination in antibody responders (n = 11)
Study: 14562195
Drug: Accelerated vaccination
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated vaccination protocol (0-7-21 days) with combined hepatitis A/B vaccine (Twinrix(R))
Study: 14562195
Drug: Standard vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vaccination scheme (0-1-6 months) with combined hepatitis A/B vaccine (Twinrix(R))
Study: 8818378
Drug: Compulsion Checklist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compulsion Checklist (CC)
Study: 28404069
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg) and velpatasvir (100 mg) for 12 weeks
Study: 28404069
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg) and velpatasvir (100 mg) for 24 weeks
Study: 28404069
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg) and velpatasvir (100 mg) plus ribavirin (weight-based 1000 mg or 1200 mg) for 12 weeks
Study: 28404069
Drug: Post-treatment (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (all groups)
Study: 22633301
Drug: Hypoglycemia (≤4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (≤4.5 mmol/L)
Study: 22633301
Drug: Severe hyperglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe hyperglycemia (>8.3 mmol/L)
Study: 22633301
Drug: Normoglycemia (4.5-5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycemia (4.5-5.5 mmol/L)
Study: 22633301
Drug: Hyperglycemic patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemic patients (>8.3 mmol/L)
Study: 17387127
Drug: PCI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI with optimal medical therapy
Study: 11880960
Drug: Acyclovir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (800 mg given by mouth 3 times per day for 2 days)
Study: 10734323
Drug: Vecuronium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium infusion of 50 microg/kg/hour following a bolus dose of 0.1 microg/kg
Study: 10734323
Drug: Atracurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium infusion of 400 microg/kg/hour following a bolus dose of 0.5 microg/kg
Study: 33863
Drug: Nadolol once
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol once daily
Study: 33863
Drug: Propranolol four
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol four times daily
Study: 33863
Drug: Nadolol once
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol once daily (extended treatment)
Study: 16436649
Drug: IM interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM interferon beta‐1a (IFNbeta‐1a) 30 microg IM once weekly for up to 5 years
Study: 16436649
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (placebo in CHAMPS)
Study: 11163733
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg, n=12)
Study: 9233974
Drug: Pacifier dipped
Normalized name: West Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacifier dipped in 24% sucrose solution
Study: 29183844
Drug: Insulin degludec/insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin degludec/insulin aspart (IDegAsp) twice daily (BID)
Study: 29183844
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30 (BIAsp 30) BID
Study: 24358145
Drug: Consistently insufficient
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistently insufficient 25(OH)D (GLL <50 nmol/l)
Study: 24358145
Drug: Consistently sufficient
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistently sufficient 25(OH)D (GHH >50 nmol/l)
Study: 20961233
Drug: Targeted narrowband
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted narrowband UVB phototherapy plus topical tetrahydrocurcuminoid cream
Study: 20961233
Drug: Targeted narrowband
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted narrowband UVB monotherapy
Study: 19008798
Drug: Pramipexole as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole as an add-on therapy to L-DOPA and amantadin
Study: 11863119
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (IVC) pulse therapy (0.75 - 1.0 g/m2 body surface area) combined with oral corticosteroid (up to 1 mg/kg/day) for 6 months
Study: 11863119
Drug: Double‐filtration plasmapheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double‐filtration plasmapheresis (DFPP) combined with corticosteroid (up to 1 mg/kg/day) performed 1-2 times weekly for 6 months
Study: 2123914
Drug: Isosorbide 5-mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide 5-mononitrate (Is-5-Mn), 40 mg b.i.d. for 3 months
Study: 30738433
Drug: Zaltoprofen 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaltoprofen 480 mg/day for 48 weeks
Study: 31161196
Drug: Plasma copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma copper (quartile 4 ≥ 117.0 μg/dL)
Study: 28601167
Drug: Nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition education (3 weekly 60-minute sessions)
Study: 12627702
Drug: 2% commercial
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% commercial chlorhexidine solution (Cav Clean) applied for 40 seconds after acid etching
Study: 12627702
Drug: 37% phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37% phosphoric acid gel containing 2% digluconate of chlorhexidine (Cond AC) for 15 seconds (Group III)
Study: 9093237
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of myeloid growth factors G-CSF and GM-CSF for neutropenia
Study: 9093237
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy for immune-mediated thrombocytopenia including zidovudine, corticosteroids, IVGG, and splenectomy
Study: 9093237
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific therapy for asymptomatic hypergammaglobulinemia and lupus anticoagulants
Study: 3579357
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon alfa‐2b (5 X 10(6) U, intramuscular)
Study: 29076028
Drug: BI 425809
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 425809 (doses: 0.5, 1, 2, 5, 10, 25, 50, 100, 150 mg)
Study: 29076028
Drug: BI 425809
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 425809 (25 mg tablet)
Study: 21925260
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of lipopolysaccharide (LPS)
Study: 18078449
Drug: Controlled-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release melatonin (5 mg)
Study: 16759445
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of tissue plasminogen activator
Study: 12846543
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia drugs
Study: 2649308
Drug: Diuretic with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic with usual diet
Study: 2649308
Drug: Diuretic with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic with weight loss diet
Study: 2649308
Drug: Diuretic with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic with low sodium/high potassium diet
Study: 2649308
Drug: Beta-blocker with
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker with usual diet
Study: 2649308
Drug: Beta-blocker with
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker with weight loss diet
Study: 2649308
Drug: Beta-blocker with
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker with low sodium/high potassium diet
Study: 25936724
Drug: AERAS-402 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: AERAS-402 (two doses across three dose levels)
Study: 25936724
Drug: AERAS-402 (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: AERAS-402 (three doses at the highest dose level)
Study: 25218194
Drug: AERAS-402 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: AERAS-402 (two doses)
Study: 23730991
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive treatment (achieved BP ≤140/90 mm Hg)
Study: 23730991
Drug: Standard antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antihypertensive treatment (achieved BP ≤150/90 mm Hg)
Study: 19672186
Drug: CR665 (0.36
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR665 (0.36 mg/kg) administered intravenously over 1 h
Study: 19672186
Drug: Oxycodone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (15 mg) administered orally
Study: 19672186
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously and orally
Study: 22328063
Drug: Artemisinin-naphthoquine (Arco®)
Normalized name: naphthoquine
DrugBank: Naphthoquine (DB16249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-naphthoquine (Arco®) - single dose (125 mg artemisinin and 50 mg naphthoquine)
Study: 22328063
Drug: Artemether-lumefantrine (Coartem®)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (Coartem®) - three-day regimen (20 mg artemether and 120 mg lumefantrine)
Study: 9658725
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by transplantation (allogeneic or autologous)
Study: 2577483
Drug: Coated 5-ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated 5-ASA (Claversal) 0.75 g/day
Study: 2577483
Drug: Sulphasalazine 1.5-2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine 1.5-2.0 g/day
Study: 23298524
Drug: Supplemental omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental omega-3 fatty acids (3.18 g daily of eicosapentaenoic acid and 822 mg daily of docosahexaenoic acid)
Study: 20859868
Drug: Montelukast 4
Normalized name: montelukast 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4 mg daily for 1 month
Study: 18445899
Drug: ESWL +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESWL + 40 mg of furosemide
Study: 12558462
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 or 100 mg/day
Study: 10338106
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g piracetam daily for 4 weeks and maintenance treatment for 8 weeks
Study: 10338106
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g piracetam
Study: 7860900
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of APSAC and rt-PA
Study: 1781340
Drug: Phenobarbital (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (administered prenatally in a small dose)
Study: 7282057
Drug: Oral loperamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loperamide, doses of 2-6 mg per day
Study: 28228428
Drug: Aggressive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive blood pressure treatment (target <120/80 mm Hg)
Study: 28228428
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment (target <140/90 mm Hg)
Study: 28228428
Drug: Aggressive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive blood pressure treatment
Study: 24096552
Drug: Copper supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper supplementation (8 mg/day as copper sulfate)
Study: 15345918
Drug: Classic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic heparin with Hemophan membrane
Study: 15345918
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin with Hemophan membrane
Study: 15345918
Drug: Classic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic heparin with ethylene vinyl alcohol membrane
Study: 15345918
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin with ethylene vinyl alcohol membrane
Study: 15345918
Drug: Classic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic heparin with polyacrylonitrile membrane
Study: 15345918
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin with polyacrylonitrile membrane
Study: 9105569
Drug: L-arginine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (7 g three times per day for 3 days)
Study: 8255447
Drug: Vigabatrin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (3 grams oral daily add-on therapy)
Study: 8255447
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily add-on therapy)
Study: 27100716
Drug: Non-anesthesiologist administration
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anesthesiologist administration of propofol (Group A)
Study: 27100716
Drug: Anesthesiologist-administered sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesiologist-administered sedation (Group B)
Study: 24177711
Drug: Halliwick‐Therapy (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halliwick‐Therapy (n = 14)
Study: 22244014
Drug: Orafti® Synergy1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orafti® Synergy1 (β2-1 fructans) 8 g/d
Study: 16204748
Drug: Abciximab with
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab with an initial heparin bolus of 50 U/kg (n = 128)
Study: 16204748
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with an initial heparin bolus of 70 U/kg (n = 126)
Study: 9498724
Drug: Ketamine (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (i.v. bolus of 0.26 mg/kg followed by an infusion of 0.65 mg/kg per hour)
Study: 9498724
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg, PO
Study: 2294135
Drug: Increased dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased dietary calcium intake (dairy products) by an average of 610 mg/day for 3 years
Study: 118329
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of chemotherapy for an additional three years
Study: 118329
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of therapy
Study: 30496350
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tribendimidine
Study: 30496350
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tribendimidine
Study: 30496350
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tribendimidine
Study: 29079039
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ethyl-EPA and vitamins E+C
Study: 24991933
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (NOT, acetazolamide, placebo)
Study: 8132440
Drug: mianserine (30-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserine (30-60 mg/day)
Study: 8132440
Drug: fluvoxamine (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluvoxamine (50-100 mg/day)
Study: 2679331
Drug: Intrathecal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal diamorphine 0.75 mg
Study: 2679331
Drug: Intrathecal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal diamorphine 1.5 mg
Study: 2679331
Drug: Intrathecal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal diamorphine 2.5 mg
Study: 2679331
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg diamorphine)
Study: 535777
Drug: Bromocryptine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocryptine 2.5 mg
Study: 22434736
Drug: Monthly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly group classes and telephone behavioural sessions
Study: 19067471
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (10-40 mg) with amlodipine 5 mg for 8 weeks
Study: 19067471
Drug: Uptitration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uptitration of olmesartan medoxomil/amlodipine to 20/5 mg, 40/5 mg, or 40/10 mg
Study: 19067471
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus amlodipine 5 mg for 8 weeks
Study: 15288987
Drug: Glasses with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasses with or without patches
Study: 15288987
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment for 1 year
Study: 9620508
Drug: Midazolam (Mz)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (Mz) in combination with Propofol (Pf)
Study: 2655365
Drug: 0.5% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% mepivacaine with epinephrine 5 micrograms/ml (3 ml at each pin site)